nodes	percent_of_prediction	percent_of_DWPC	metapath
Bicalutamide—CYP2D6—Hydroxyurea—psoriasis	0.0615	0.102	CbGbCtD
Bicalutamide—CYP2C19—Cholecalciferol—psoriasis	0.049	0.0815	CbGbCtD
Bicalutamide—CYP3A4—Calcitriol—psoriasis	0.046	0.0765	CbGbCtD
Bicalutamide—CYP2C9—Cholecalciferol—psoriasis	0.0407	0.0678	CbGbCtD
Bicalutamide—CYP2D6—Cholecalciferol—psoriasis	0.0372	0.062	CbGbCtD
Bicalutamide—CYP3A4—Methoxsalen—psoriasis	0.0357	0.0595	CbGbCtD
Bicalutamide—CYP2C19—Prednisone—psoriasis	0.0339	0.0565	CbGbCtD
Bicalutamide—CYP2C19—Cyclosporine—psoriasis	0.0322	0.0536	CbGbCtD
Bicalutamide—CYP2C9—Cyclosporine—psoriasis	0.0268	0.0445	CbGbCtD
Bicalutamide—CYP2D6—Cyclosporine—psoriasis	0.0245	0.0407	CbGbCtD
Bicalutamide—CYP3A4—Cholecalciferol—psoriasis	0.0237	0.0394	CbGbCtD
Bicalutamide—CYP2C19—Dexamethasone—psoriasis	0.0212	0.0353	CbGbCtD
Bicalutamide—CYP3A4—Triamcinolone—psoriasis	0.0205	0.0342	CbGbCtD
Bicalutamide—CYP3A4—Mycophenolate mofetil—psoriasis	0.0205	0.0342	CbGbCtD
Bicalutamide—CYP2C9—Dexamethasone—psoriasis	0.0176	0.0293	CbGbCtD
Bicalutamide—CYP3A4—Betamethasone—psoriasis	0.0176	0.0293	CbGbCtD
Bicalutamide—CYP3A4—Prednisolone—psoriasis	0.0174	0.0289	CbGbCtD
Bicalutamide—CYP3A4—Hydrocortisone—psoriasis	0.0165	0.0274	CbGbCtD
Bicalutamide—CYP3A4—Prednisone—psoriasis	0.0164	0.0273	CbGbCtD
Bicalutamide—CYP2D6—Dexamethasone—psoriasis	0.0161	0.0268	CbGbCtD
Bicalutamide—CYP3A4—Cyclosporine—psoriasis	0.0156	0.0259	CbGbCtD
Bicalutamide—CYP3A4—Dexamethasone—psoriasis	0.0102	0.0171	CbGbCtD
Bicalutamide—CYP2C19—CYP2E1 reactions—CYP2S1—psoriasis	0.002	0.0629	CbGpPWpGaD
Bicalutamide—CYP2D6—CYP2E1 reactions—CYP2S1—psoriasis	0.00184	0.0578	CbGpPWpGaD
Bicalutamide—CYP2C9—CYP2E1 reactions—CYP2S1—psoriasis	0.00183	0.0573	CbGpPWpGaD
Bicalutamide—CYP2D6—Miscellaneous substrates—CYP2S1—psoriasis	0.00172	0.0539	CbGpPWpGaD
Bicalutamide—CYP2C19—Xenobiotics—CYP2S1—psoriasis	0.00124	0.039	CbGpPWpGaD
Bicalutamide—CYP2D6—Xenobiotics—CYP2S1—psoriasis	0.00114	0.0358	CbGpPWpGaD
Bicalutamide—CYP2C9—Xenobiotics—CYP2S1—psoriasis	0.00113	0.0355	CbGpPWpGaD
Bicalutamide—AR—Coregulation of Androgen receptor activity—ZMIZ1—psoriasis	0.000924	0.029	CbGpPWpGaD
Bicalutamide—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000747	0.0234	CbGpPWpGaD
Bicalutamide—AR—Androgen receptor signaling pathway—ZMIZ1—psoriasis	0.000683	0.0214	CbGpPWpGaD
Bicalutamide—AR—Regulation of Androgen receptor activity—REL—psoriasis	0.000677	0.0212	CbGpPWpGaD
Bicalutamide—AR—Regulation of Androgen receptor activity—CARM1—psoriasis	0.000666	0.0209	CbGpPWpGaD
Bicalutamide—AR—Coregulation of Androgen receptor activity—CARM1—psoriasis	0.000596	0.0187	CbGpPWpGaD
Bicalutamide—AR—Regulation of nuclear SMAD2/3 signaling—RUNX3—psoriasis	0.000558	0.0175	CbGpPWpGaD
Bicalutamide—AR—Nuclear Receptors—VDR—psoriasis	0.000519	0.0163	CbGpPWpGaD
Bicalutamide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000516	0.0162	CbGpPWpGaD
Bicalutamide—CYP2C19—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000509	0.016	CbGpPWpGaD
Bicalutamide—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000475	0.0149	CbGpPWpGaD
Bicalutamide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000471	0.0148	CbGpPWpGaD
Bicalutamide—CYP2D6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000468	0.0147	CbGpPWpGaD
Bicalutamide—CYP2C9—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000464	0.0146	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—ZMIZ1—psoriasis	0.000448	0.014	CbGpPWpGaD
Bicalutamide—AR—Androgen receptor signaling pathway—CARM1—psoriasis	0.00044	0.0138	CbGpPWpGaD
Bicalutamide—CYP2C19—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000418	0.0131	CbGpPWpGaD
Bicalutamide—AR—Nuclear Receptor transcription pathway—VDR—psoriasis	0.00041	0.0129	CbGpPWpGaD
Bicalutamide—CYP2D6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000385	0.0121	CbGpPWpGaD
Bicalutamide—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000381	0.012	CbGpPWpGaD
Bicalutamide—AR—Nuclear Receptors—PPARG—psoriasis	0.000362	0.0114	CbGpPWpGaD
Bicalutamide—AR—SIDS Susceptibility Pathways—RUNX3—psoriasis	0.00033	0.0104	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	0.000311	0.00974	CbGpPWpGaD
Bicalutamide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.00031	0.00973	CbGpPWpGaD
Bicalutamide—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000306	0.0096	CbGpPWpGaD
Bicalutamide—AR—Nuclear Receptor transcription pathway—PPARG—psoriasis	0.000286	0.00897	CbGpPWpGaD
Bicalutamide—AR—Regulation of nuclear SMAD2/3 signaling—VDR—psoriasis	0.000283	0.00889	CbGpPWpGaD
Bicalutamide—AR—Regulation of nuclear SMAD2/3 signaling—IL10—psoriasis	0.000276	0.00865	CbGpPWpGaD
Bicalutamide—AR—SIDS Susceptibility Pathways—IL13—psoriasis	0.000261	0.00818	CbGpPWpGaD
Bicalutamide—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000252	0.00789	CbGpPWpGaD
Bicalutamide—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000248	0.00778	CbGpPWpGaD
Bicalutamide—AR—Notch-mediated HES/HEY network—CD4—psoriasis	0.000242	0.00759	CbGpPWpGaD
Bicalutamide—AR—FOXA1 transcription factor network—JUN—psoriasis	0.000228	0.00716	CbGpPWpGaD
Bicalutamide—CYP2C19—Biological oxidations—CYP2S1—psoriasis	0.000222	0.00697	CbGpPWpGaD
Bicalutamide—CYP2C19—Metapathway biotransformation—CYP2S1—psoriasis	0.000219	0.00687	CbGpPWpGaD
Bicalutamide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000216	0.00678	CbGpPWpGaD
Bicalutamide—CYP2C19—Melatonin metabolism and effects—APOE—psoriasis	0.000215	0.00676	CbGpPWpGaD
Bicalutamide—CYP2D6—Biological oxidations—CYP2S1—psoriasis	0.000204	0.00641	CbGpPWpGaD
Bicalutamide—CYP2C9—Biological oxidations—CYP2S1—psoriasis	0.000203	0.00635	CbGpPWpGaD
Bicalutamide—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	0.000202	0.00632	CbGpPWpGaD
Bicalutamide—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	0.0002	0.00627	CbGpPWpGaD
Bicalutamide—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	0.000198	0.00621	CbGpPWpGaD
Bicalutamide—AR—Regulation of Androgen receptor activity—JUN—psoriasis	0.000197	0.00617	CbGpPWpGaD
Bicalutamide—AR—Notch-mediated HES/HEY network—STAT3—psoriasis	0.000187	0.00588	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—TARS—psoriasis	0.000182	0.00569	CbGpPWpGaD
Bicalutamide—AR—SIDS Susceptibility Pathways—IL10—psoriasis	0.000163	0.00512	CbGpPWpGaD
Bicalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CXCL8—psoriasis	0.000152	0.00477	CbGpPWpGaD
Bicalutamide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000151	0.00472	CbGpPWpGaD
Bicalutamide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000143	0.00447	CbGpPWpGaD
Bicalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—JUN—psoriasis	0.000142	0.00444	CbGpPWpGaD
Bicalutamide—AR—Regulation of nuclear SMAD2/3 signaling—JUN—psoriasis	0.00014	0.00439	CbGpPWpGaD
Bicalutamide—CYP3A4—Biological oxidations—CYP2S1—psoriasis	0.000134	0.00419	CbGpPWpGaD
Bicalutamide—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	0.000132	0.00413	CbGpPWpGaD
Bicalutamide—AR—Androgen receptor signaling pathway—JUN—psoriasis	0.00013	0.00408	CbGpPWpGaD
Bicalutamide—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	0.000128	0.00402	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	0.000127	0.00397	CbGpPWpGaD
Bicalutamide—Shock—Triamcinolone—psoriasis	0.000121	0.000329	CcSEcCtD
Bicalutamide—Insomnia—Prednisolone—psoriasis	0.000121	0.000329	CcSEcCtD
Bicalutamide—Alopecia—Prednisone—psoriasis	0.000121	0.000329	CcSEcCtD
Bicalutamide—Hepatobiliary disease—Methotrexate—psoriasis	0.00012	0.000327	CcSEcCtD
Bicalutamide—Gastrointestinal pain—Cyclosporine—psoriasis	0.00012	0.000327	CcSEcCtD
Bicalutamide—Loss of consciousness—Betamethasone—psoriasis	0.00012	0.000327	CcSEcCtD
Bicalutamide—Loss of consciousness—Dexamethasone—psoriasis	0.00012	0.000327	CcSEcCtD
Bicalutamide—Dizziness—Mycophenolic acid—psoriasis	0.00012	0.000327	CcSEcCtD
Bicalutamide—Epistaxis—Methotrexate—psoriasis	0.00012	0.000326	CcSEcCtD
Bicalutamide—Paraesthesia—Prednisolone—psoriasis	0.00012	0.000326	CcSEcCtD
Bicalutamide—Mental disorder—Prednisone—psoriasis	0.00012	0.000326	CcSEcCtD
Bicalutamide—Malnutrition—Prednisone—psoriasis	0.000119	0.000324	CcSEcCtD
Bicalutamide—Musculoskeletal discomfort—Hydrocortisone—psoriasis	0.000119	0.000323	CcSEcCtD
Bicalutamide—AR—Generic Transcription Pathway—CARM1—psoriasis	0.000119	0.00372	CbGpPWpGaD
Bicalutamide—Hyperhidrosis—Triamcinolone—psoriasis	0.000119	0.000323	CcSEcCtD
Bicalutamide—Feeling abnormal—Mycophenolate mofetil—psoriasis	0.000118	0.000321	CcSEcCtD
Bicalutamide—Insomnia—Hydrocortisone—psoriasis	0.000118	0.000321	CcSEcCtD
Bicalutamide—Hypertension—Dexamethasone—psoriasis	0.000118	0.000321	CcSEcCtD
Bicalutamide—Hypertension—Betamethasone—psoriasis	0.000118	0.000321	CcSEcCtD
Bicalutamide—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	0.000118	0.0037	CbGpPWpGaD
Bicalutamide—Paraesthesia—Hydrocortisone—psoriasis	0.000117	0.000319	CcSEcCtD
Bicalutamide—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.000117	0.000319	CcSEcCtD
Bicalutamide—Urticaria—Cyclosporine—psoriasis	0.000117	0.000317	CcSEcCtD
Bicalutamide—Myalgia—Dexamethasone—psoriasis	0.000116	0.000316	CcSEcCtD
Bicalutamide—Myalgia—Betamethasone—psoriasis	0.000116	0.000316	CcSEcCtD
Bicalutamide—Body temperature increased—Cyclosporine—psoriasis	0.000116	0.000316	CcSEcCtD
Bicalutamide—Abdominal pain—Cyclosporine—psoriasis	0.000116	0.000316	CcSEcCtD
Bicalutamide—Anxiety—Dexamethasone—psoriasis	0.000116	0.000315	CcSEcCtD
Bicalutamide—Anxiety—Betamethasone—psoriasis	0.000116	0.000315	CcSEcCtD
Bicalutamide—Vomiting—Mycophenolic acid—psoriasis	0.000115	0.000314	CcSEcCtD
Bicalutamide—CYP3A4—Tryptophan metabolism—CAT—psoriasis	0.000115	0.00361	CbGpPWpGaD
Bicalutamide—Dyspepsia—Hydrocortisone—psoriasis	0.000115	0.000313	CcSEcCtD
Bicalutamide—Haemoglobin—Methotrexate—psoriasis	0.000115	0.000312	CcSEcCtD
Bicalutamide—Rash—Mycophenolic acid—psoriasis	0.000114	0.000311	CcSEcCtD
Bicalutamide—Dermatitis—Mycophenolic acid—psoriasis	0.000114	0.000311	CcSEcCtD
Bicalutamide—Pain—Prednisolone—psoriasis	0.000114	0.000311	CcSEcCtD
Bicalutamide—Haemorrhage—Methotrexate—psoriasis	0.000114	0.000311	CcSEcCtD
Bicalutamide—Urticaria—Mycophenolate mofetil—psoriasis	0.000114	0.00031	CcSEcCtD
Bicalutamide—Headache—Mycophenolic acid—psoriasis	0.000114	0.000309	CcSEcCtD
Bicalutamide—Decreased appetite—Hydrocortisone—psoriasis	0.000113	0.000309	CcSEcCtD
Bicalutamide—Pharyngitis—Methotrexate—psoriasis	0.000113	0.000308	CcSEcCtD
Bicalutamide—Body temperature increased—Mycophenolate mofetil—psoriasis	0.000113	0.000308	CcSEcCtD
Bicalutamide—Abdominal pain—Mycophenolate mofetil—psoriasis	0.000113	0.000308	CcSEcCtD
Bicalutamide—Urinary tract disorder—Methotrexate—psoriasis	0.000113	0.000307	CcSEcCtD
Bicalutamide—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000113	0.000307	CcSEcCtD
Bicalutamide—AR—Androgen receptor signaling pathway—STAT3—psoriasis	0.000112	0.00353	CbGpPWpGaD
Bicalutamide—Fatigue—Hydrocortisone—psoriasis	0.000112	0.000306	CcSEcCtD
Bicalutamide—Urethral disorder—Methotrexate—psoriasis	0.000112	0.000305	CcSEcCtD
Bicalutamide—Musculoskeletal discomfort—Triamcinolone—psoriasis	0.000112	0.000305	CcSEcCtD
Bicalutamide—Pain—Hydrocortisone—psoriasis	0.000112	0.000304	CcSEcCtD
Bicalutamide—Oedema—Betamethasone—psoriasis	0.000111	0.000303	CcSEcCtD
Bicalutamide—Oedema—Dexamethasone—psoriasis	0.000111	0.000303	CcSEcCtD
Bicalutamide—Insomnia—Triamcinolone—psoriasis	0.000111	0.000302	CcSEcCtD
Bicalutamide—Infection—Dexamethasone—psoriasis	0.000111	0.000301	CcSEcCtD
Bicalutamide—Infection—Betamethasone—psoriasis	0.000111	0.000301	CcSEcCtD
Bicalutamide—Paraesthesia—Triamcinolone—psoriasis	0.00011	0.0003	CcSEcCtD
Bicalutamide—Feeling abnormal—Prednisolone—psoriasis	0.00011	0.0003	CcSEcCtD
Bicalutamide—Visual impairment—Methotrexate—psoriasis	0.00011	0.000299	CcSEcCtD
Bicalutamide—Anaemia—Prednisone—psoriasis	0.00011	0.000299	CcSEcCtD
Bicalutamide—Shock—Betamethasone—psoriasis	0.00011	0.000298	CcSEcCtD
Bicalutamide—Shock—Dexamethasone—psoriasis	0.00011	0.000298	CcSEcCtD
Bicalutamide—Dyspnoea—Triamcinolone—psoriasis	0.000109	0.000298	CcSEcCtD
Bicalutamide—Nervous system disorder—Dexamethasone—psoriasis	0.000109	0.000297	CcSEcCtD
Bicalutamide—Nervous system disorder—Betamethasone—psoriasis	0.000109	0.000297	CcSEcCtD
Bicalutamide—Thrombocytopenia—Dexamethasone—psoriasis	0.000109	0.000297	CcSEcCtD
Bicalutamide—Thrombocytopenia—Betamethasone—psoriasis	0.000109	0.000297	CcSEcCtD
Bicalutamide—Angioedema—Prednisone—psoriasis	0.000109	0.000296	CcSEcCtD
Bicalutamide—Hypersensitivity—Cyclosporine—psoriasis	0.000108	0.000294	CcSEcCtD
Bicalutamide—Dyspepsia—Triamcinolone—psoriasis	0.000108	0.000294	CcSEcCtD
Bicalutamide—Nausea—Mycophenolic acid—psoriasis	0.000108	0.000293	CcSEcCtD
Bicalutamide—Hyperhidrosis—Dexamethasone—psoriasis	0.000108	0.000293	CcSEcCtD
Bicalutamide—Hyperhidrosis—Betamethasone—psoriasis	0.000108	0.000293	CcSEcCtD
Bicalutamide—Feeling abnormal—Hydrocortisone—psoriasis	0.000107	0.000293	CcSEcCtD
Bicalutamide—Gastrointestinal pain—Hydrocortisone—psoriasis	0.000107	0.00029	CcSEcCtD
Bicalutamide—Syncope—Prednisone—psoriasis	0.000107	0.00029	CcSEcCtD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	0.000106	0.00334	CbGpPWpGaD
Bicalutamide—Anorexia—Betamethasone—psoriasis	0.000106	0.000289	CcSEcCtD
Bicalutamide—Anorexia—Dexamethasone—psoriasis	0.000106	0.000289	CcSEcCtD
Bicalutamide—Urticaria—Prednisolone—psoriasis	0.000106	0.000289	CcSEcCtD
Bicalutamide—Cardiac disorder—Methotrexate—psoriasis	0.000106	0.000288	CcSEcCtD
Bicalutamide—Fatigue—Triamcinolone—psoriasis	0.000106	0.000288	CcSEcCtD
Bicalutamide—Hypersensitivity—Mycophenolate mofetil—psoriasis	0.000105	0.000287	CcSEcCtD
Bicalutamide—Asthenia—Cyclosporine—psoriasis	0.000105	0.000287	CcSEcCtD
Bicalutamide—Pain—Triamcinolone—psoriasis	0.000105	0.000286	CcSEcCtD
Bicalutamide—Loss of consciousness—Prednisone—psoriasis	0.000104	0.000284	CcSEcCtD
Bicalutamide—Pruritus—Cyclosporine—psoriasis	0.000104	0.000283	CcSEcCtD
Bicalutamide—Urticaria—Hydrocortisone—psoriasis	0.000104	0.000282	CcSEcCtD
Bicalutamide—Angiopathy—Methotrexate—psoriasis	0.000104	0.000282	CcSEcCtD
Bicalutamide—Immune system disorder—Methotrexate—psoriasis	0.000103	0.000281	CcSEcCtD
Bicalutamide—Abdominal pain—Hydrocortisone—psoriasis	0.000103	0.000281	CcSEcCtD
Bicalutamide—Body temperature increased—Hydrocortisone—psoriasis	0.000103	0.000281	CcSEcCtD
Bicalutamide—Mediastinal disorder—Methotrexate—psoriasis	0.000103	0.00028	CcSEcCtD
Bicalutamide—Asthenia—Mycophenolate mofetil—psoriasis	0.000103	0.00028	CcSEcCtD
Bicalutamide—Hypertension—Prednisone—psoriasis	0.000103	0.000279	CcSEcCtD
Bicalutamide—Chills—Methotrexate—psoriasis	0.000102	0.000279	CcSEcCtD
Bicalutamide—Musculoskeletal discomfort—Betamethasone—psoriasis	0.000102	0.000276	CcSEcCtD
Bicalutamide—Musculoskeletal discomfort—Dexamethasone—psoriasis	0.000102	0.000276	CcSEcCtD
Bicalutamide—Pruritus—Mycophenolate mofetil—psoriasis	0.000101	0.000276	CcSEcCtD
Bicalutamide—Myalgia—Prednisone—psoriasis	0.000101	0.000276	CcSEcCtD
Bicalutamide—Feeling abnormal—Triamcinolone—psoriasis	0.000101	0.000275	CcSEcCtD
Bicalutamide—Anxiety—Prednisone—psoriasis	0.000101	0.000275	CcSEcCtD
Bicalutamide—Alopecia—Methotrexate—psoriasis	0.000101	0.000275	CcSEcCtD
Bicalutamide—Insomnia—Betamethasone—psoriasis	0.000101	0.000274	CcSEcCtD
Bicalutamide—Insomnia—Dexamethasone—psoriasis	0.000101	0.000274	CcSEcCtD
Bicalutamide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	0.000101	0.000274	CcSEcCtD
Bicalutamide—Diarrhoea—Cyclosporine—psoriasis	0.0001	0.000273	CcSEcCtD
Bicalutamide—Paraesthesia—Betamethasone—psoriasis	0.0001	0.000272	CcSEcCtD
Bicalutamide—Paraesthesia—Dexamethasone—psoriasis	0.0001	0.000272	CcSEcCtD
Bicalutamide—Mental disorder—Methotrexate—psoriasis	0.0001	0.000272	CcSEcCtD
Bicalutamide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	9.94e-05	0.00312	CbGpPWpGaD
Bicalutamide—Malnutrition—Methotrexate—psoriasis	9.94e-05	0.000271	CcSEcCtD
Bicalutamide—Hypersensitivity—Prednisolone—psoriasis	9.84e-05	0.000268	CcSEcCtD
Bicalutamide—Dyspepsia—Dexamethasone—psoriasis	9.81e-05	0.000267	CcSEcCtD
Bicalutamide—Dyspepsia—Betamethasone—psoriasis	9.81e-05	0.000267	CcSEcCtD
Bicalutamide—Diarrhoea—Mycophenolate mofetil—psoriasis	9.79e-05	0.000267	CcSEcCtD
Bicalutamide—Urticaria—Triamcinolone—psoriasis	9.76e-05	0.000266	CcSEcCtD
Bicalutamide—Body temperature increased—Triamcinolone—psoriasis	9.71e-05	0.000264	CcSEcCtD
Bicalutamide—Dizziness—Cyclosporine—psoriasis	9.7e-05	0.000264	CcSEcCtD
Bicalutamide—Oedema—Prednisone—psoriasis	9.7e-05	0.000264	CcSEcCtD
Bicalutamide—Decreased appetite—Dexamethasone—psoriasis	9.69e-05	0.000264	CcSEcCtD
Bicalutamide—Decreased appetite—Betamethasone—psoriasis	9.69e-05	0.000264	CcSEcCtD
Bicalutamide—Infection—Prednisone—psoriasis	9.64e-05	0.000262	CcSEcCtD
Bicalutamide—Gastrointestinal disorder—Betamethasone—psoriasis	9.62e-05	0.000262	CcSEcCtD
Bicalutamide—Gastrointestinal disorder—Dexamethasone—psoriasis	9.62e-05	0.000262	CcSEcCtD
Bicalutamide—Back pain—Methotrexate—psoriasis	9.61e-05	0.000262	CcSEcCtD
Bicalutamide—Hypersensitivity—Hydrocortisone—psoriasis	9.61e-05	0.000262	CcSEcCtD
Bicalutamide—Fatigue—Betamethasone—psoriasis	9.61e-05	0.000262	CcSEcCtD
Bicalutamide—Fatigue—Dexamethasone—psoriasis	9.61e-05	0.000262	CcSEcCtD
Bicalutamide—Shock—Prednisone—psoriasis	9.55e-05	0.00026	CcSEcCtD
Bicalutamide—Pain—Betamethasone—psoriasis	9.53e-05	0.000259	CcSEcCtD
Bicalutamide—Pain—Dexamethasone—psoriasis	9.53e-05	0.000259	CcSEcCtD
Bicalutamide—Nervous system disorder—Prednisone—psoriasis	9.52e-05	0.000259	CcSEcCtD
Bicalutamide—Dizziness—Mycophenolate mofetil—psoriasis	9.47e-05	0.000258	CcSEcCtD
Bicalutamide—Skin disorder—Prednisone—psoriasis	9.42e-05	0.000257	CcSEcCtD
Bicalutamide—Hyperhidrosis—Prednisone—psoriasis	9.38e-05	0.000255	CcSEcCtD
Bicalutamide—Asthenia—Hydrocortisone—psoriasis	9.36e-05	0.000255	CcSEcCtD
Bicalutamide—Vomiting—Cyclosporine—psoriasis	9.33e-05	0.000254	CcSEcCtD
Bicalutamide—Rash—Cyclosporine—psoriasis	9.25e-05	0.000252	CcSEcCtD
Bicalutamide—Anorexia—Prednisone—psoriasis	9.25e-05	0.000252	CcSEcCtD
Bicalutamide—Dermatitis—Cyclosporine—psoriasis	9.24e-05	0.000252	CcSEcCtD
Bicalutamide—Pruritus—Hydrocortisone—psoriasis	9.23e-05	0.000251	CcSEcCtD
Bicalutamide—Headache—Cyclosporine—psoriasis	9.19e-05	0.00025	CcSEcCtD
Bicalutamide—Anaemia—Methotrexate—psoriasis	9.18e-05	0.00025	CcSEcCtD
Bicalutamide—Feeling abnormal—Dexamethasone—psoriasis	9.18e-05	0.00025	CcSEcCtD
Bicalutamide—Feeling abnormal—Betamethasone—psoriasis	9.18e-05	0.00025	CcSEcCtD
Bicalutamide—Gastrointestinal pain—Betamethasone—psoriasis	9.11e-05	0.000248	CcSEcCtD
Bicalutamide—Gastrointestinal pain—Dexamethasone—psoriasis	9.11e-05	0.000248	CcSEcCtD
Bicalutamide—Vomiting—Mycophenolate mofetil—psoriasis	9.1e-05	0.000248	CcSEcCtD
Bicalutamide—Hypersensitivity—Triamcinolone—psoriasis	9.05e-05	0.000246	CcSEcCtD
Bicalutamide—Rash—Mycophenolate mofetil—psoriasis	9.03e-05	0.000246	CcSEcCtD
Bicalutamide—Dermatitis—Mycophenolate mofetil—psoriasis	9.02e-05	0.000245	CcSEcCtD
Bicalutamide—Headache—Mycophenolate mofetil—psoriasis	8.97e-05	0.000244	CcSEcCtD
Bicalutamide—AR—SIDS Susceptibility Pathways—CXCL8—psoriasis	8.92e-05	0.0028	CbGpPWpGaD
Bicalutamide—Diarrhoea—Hydrocortisone—psoriasis	8.92e-05	0.000243	CcSEcCtD
Bicalutamide—Urticaria—Dexamethasone—psoriasis	8.85e-05	0.000241	CcSEcCtD
Bicalutamide—Urticaria—Betamethasone—psoriasis	8.85e-05	0.000241	CcSEcCtD
Bicalutamide—Musculoskeletal discomfort—Prednisone—psoriasis	8.84e-05	0.000241	CcSEcCtD
Bicalutamide—Dizziness—Prednisolone—psoriasis	8.83e-05	0.00024	CcSEcCtD
Bicalutamide—Asthenia—Triamcinolone—psoriasis	8.81e-05	0.00024	CcSEcCtD
Bicalutamide—Body temperature increased—Dexamethasone—psoriasis	8.81e-05	0.00024	CcSEcCtD
Bicalutamide—Abdominal pain—Dexamethasone—psoriasis	8.81e-05	0.00024	CcSEcCtD
Bicalutamide—Abdominal pain—Betamethasone—psoriasis	8.81e-05	0.00024	CcSEcCtD
Bicalutamide—Body temperature increased—Betamethasone—psoriasis	8.81e-05	0.00024	CcSEcCtD
Bicalutamide—Insomnia—Prednisone—psoriasis	8.78e-05	0.000239	CcSEcCtD
Bicalutamide—Nausea—Cyclosporine—psoriasis	8.72e-05	0.000237	CcSEcCtD
Bicalutamide—Paraesthesia—Prednisone—psoriasis	8.71e-05	0.000237	CcSEcCtD
Bicalutamide—Pruritus—Triamcinolone—psoriasis	8.69e-05	0.000237	CcSEcCtD
Bicalutamide—Cough—Methotrexate—psoriasis	8.67e-05	0.000236	CcSEcCtD
Bicalutamide—Dizziness—Hydrocortisone—psoriasis	8.62e-05	0.000235	CcSEcCtD
Bicalutamide—Dyspepsia—Prednisone—psoriasis	8.54e-05	0.000233	CcSEcCtD
Bicalutamide—AR—Integrated Breast Cancer Pathway—JUN—psoriasis	8.52e-05	0.00267	CbGpPWpGaD
Bicalutamide—Nausea—Mycophenolate mofetil—psoriasis	8.5e-05	0.000231	CcSEcCtD
Bicalutamide—Myalgia—Methotrexate—psoriasis	8.46e-05	0.00023	CcSEcCtD
Bicalutamide—Chest pain—Methotrexate—psoriasis	8.46e-05	0.00023	CcSEcCtD
Bicalutamide—Decreased appetite—Prednisone—psoriasis	8.43e-05	0.00023	CcSEcCtD
Bicalutamide—Rash—Prednisolone—psoriasis	8.42e-05	0.000229	CcSEcCtD
Bicalutamide—Dermatitis—Prednisolone—psoriasis	8.41e-05	0.000229	CcSEcCtD
Bicalutamide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	8.4e-05	0.000229	CcSEcCtD
Bicalutamide—Fatigue—Prednisone—psoriasis	8.37e-05	0.000228	CcSEcCtD
Bicalutamide—Headache—Prednisolone—psoriasis	8.37e-05	0.000228	CcSEcCtD
Bicalutamide—Constipation—Prednisone—psoriasis	8.3e-05	0.000226	CcSEcCtD
Bicalutamide—AR—SIDS Susceptibility Pathways—JUN—psoriasis	8.3e-05	0.0026	CbGpPWpGaD
Bicalutamide—Vomiting—Hydrocortisone—psoriasis	8.29e-05	0.000226	CcSEcCtD
Bicalutamide—Rash—Hydrocortisone—psoriasis	8.22e-05	0.000224	CcSEcCtD
Bicalutamide—Dermatitis—Hydrocortisone—psoriasis	8.22e-05	0.000224	CcSEcCtD
Bicalutamide—AR—Integrated Breast Cancer Pathway—NFKB1—psoriasis	8.2e-05	0.00257	CbGpPWpGaD
Bicalutamide—Confusional state—Methotrexate—psoriasis	8.18e-05	0.000223	CcSEcCtD
Bicalutamide—Headache—Hydrocortisone—psoriasis	8.17e-05	0.000222	CcSEcCtD
Bicalutamide—Dizziness—Triamcinolone—psoriasis	8.12e-05	0.000221	CcSEcCtD
Bicalutamide—Infection—Methotrexate—psoriasis	8.06e-05	0.000219	CcSEcCtD
Bicalutamide—Feeling abnormal—Prednisone—psoriasis	8e-05	0.000218	CcSEcCtD
Bicalutamide—Asthenia—Dexamethasone—psoriasis	7.99e-05	0.000218	CcSEcCtD
Bicalutamide—Asthenia—Betamethasone—psoriasis	7.99e-05	0.000218	CcSEcCtD
Bicalutamide—AR—SIDS Susceptibility Pathways—NFKB1—psoriasis	7.99e-05	0.0025	CbGpPWpGaD
Bicalutamide—Nervous system disorder—Methotrexate—psoriasis	7.95e-05	0.000217	CcSEcCtD
Bicalutamide—Thrombocytopenia—Methotrexate—psoriasis	7.94e-05	0.000216	CcSEcCtD
Bicalutamide—Gastrointestinal pain—Prednisone—psoriasis	7.93e-05	0.000216	CcSEcCtD
Bicalutamide—Nausea—Prednisolone—psoriasis	7.93e-05	0.000216	CcSEcCtD
Bicalutamide—Pruritus—Dexamethasone—psoriasis	7.88e-05	0.000215	CcSEcCtD
Bicalutamide—Pruritus—Betamethasone—psoriasis	7.88e-05	0.000215	CcSEcCtD
Bicalutamide—Skin disorder—Methotrexate—psoriasis	7.88e-05	0.000214	CcSEcCtD
Bicalutamide—Hyperhidrosis—Methotrexate—psoriasis	7.84e-05	0.000213	CcSEcCtD
Bicalutamide—Vomiting—Triamcinolone—psoriasis	7.81e-05	0.000213	CcSEcCtD
Bicalutamide—Nausea—Hydrocortisone—psoriasis	7.75e-05	0.000211	CcSEcCtD
Bicalutamide—Rash—Triamcinolone—psoriasis	7.74e-05	0.000211	CcSEcCtD
Bicalutamide—Dermatitis—Triamcinolone—psoriasis	7.74e-05	0.000211	CcSEcCtD
Bicalutamide—Anorexia—Methotrexate—psoriasis	7.73e-05	0.00021	CcSEcCtD
Bicalutamide—Urticaria—Prednisone—psoriasis	7.71e-05	0.00021	CcSEcCtD
Bicalutamide—Headache—Triamcinolone—psoriasis	7.69e-05	0.000209	CcSEcCtD
Bicalutamide—Abdominal pain—Prednisone—psoriasis	7.67e-05	0.000209	CcSEcCtD
Bicalutamide—Body temperature increased—Prednisone—psoriasis	7.67e-05	0.000209	CcSEcCtD
Bicalutamide—Diarrhoea—Dexamethasone—psoriasis	7.62e-05	0.000208	CcSEcCtD
Bicalutamide—Diarrhoea—Betamethasone—psoriasis	7.62e-05	0.000208	CcSEcCtD
Bicalutamide—AR—Integrated Breast Cancer Pathway—VEGFA—psoriasis	7.44e-05	0.00233	CbGpPWpGaD
Bicalutamide—Musculoskeletal discomfort—Methotrexate—psoriasis	7.39e-05	0.000201	CcSEcCtD
Bicalutamide—Dizziness—Dexamethasone—psoriasis	7.37e-05	0.000201	CcSEcCtD
Bicalutamide—Dizziness—Betamethasone—psoriasis	7.37e-05	0.000201	CcSEcCtD
Bicalutamide—Insomnia—Methotrexate—psoriasis	7.33e-05	0.0002	CcSEcCtD
Bicalutamide—Nausea—Triamcinolone—psoriasis	7.29e-05	0.000199	CcSEcCtD
Bicalutamide—Paraesthesia—Methotrexate—psoriasis	7.28e-05	0.000198	CcSEcCtD
Bicalutamide—AR—SIDS Susceptibility Pathways—VEGFA—psoriasis	7.25e-05	0.00227	CbGpPWpGaD
Bicalutamide—Dyspnoea—Methotrexate—psoriasis	7.23e-05	0.000197	CcSEcCtD
Bicalutamide—Somnolence—Methotrexate—psoriasis	7.21e-05	0.000196	CcSEcCtD
Bicalutamide—Hypersensitivity—Prednisone—psoriasis	7.15e-05	0.000195	CcSEcCtD
Bicalutamide—Dyspepsia—Methotrexate—psoriasis	7.14e-05	0.000194	CcSEcCtD
Bicalutamide—AR—Generic Transcription Pathway—VDR—psoriasis	7.09e-05	0.00222	CbGpPWpGaD
Bicalutamide—Vomiting—Dexamethasone—psoriasis	7.08e-05	0.000193	CcSEcCtD
Bicalutamide—Vomiting—Betamethasone—psoriasis	7.08e-05	0.000193	CcSEcCtD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	7.06e-05	0.00221	CbGpPWpGaD
Bicalutamide—Decreased appetite—Methotrexate—psoriasis	7.05e-05	0.000192	CcSEcCtD
Bicalutamide—Rash—Dexamethasone—psoriasis	7.03e-05	0.000191	CcSEcCtD
Bicalutamide—Rash—Betamethasone—psoriasis	7.03e-05	0.000191	CcSEcCtD
Bicalutamide—Dermatitis—Betamethasone—psoriasis	7.02e-05	0.000191	CcSEcCtD
Bicalutamide—Dermatitis—Dexamethasone—psoriasis	7.02e-05	0.000191	CcSEcCtD
Bicalutamide—Gastrointestinal disorder—Methotrexate—psoriasis	7e-05	0.000191	CcSEcCtD
Bicalutamide—Fatigue—Methotrexate—psoriasis	6.99e-05	0.00019	CcSEcCtD
Bicalutamide—Headache—Betamethasone—psoriasis	6.98e-05	0.00019	CcSEcCtD
Bicalutamide—Headache—Dexamethasone—psoriasis	6.98e-05	0.00019	CcSEcCtD
Bicalutamide—Asthenia—Prednisone—psoriasis	6.96e-05	0.00019	CcSEcCtD
Bicalutamide—Pain—Methotrexate—psoriasis	6.93e-05	0.000189	CcSEcCtD
Bicalutamide—Pruritus—Prednisone—psoriasis	6.86e-05	0.000187	CcSEcCtD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	6.79e-05	0.00213	CbGpPWpGaD
Bicalutamide—Feeling abnormal—Methotrexate—psoriasis	6.68e-05	0.000182	CcSEcCtD
Bicalutamide—Diarrhoea—Prednisone—psoriasis	6.64e-05	0.000181	CcSEcCtD
Bicalutamide—Gastrointestinal pain—Methotrexate—psoriasis	6.63e-05	0.000181	CcSEcCtD
Bicalutamide—Nausea—Betamethasone—psoriasis	6.62e-05	0.00018	CcSEcCtD
Bicalutamide—Nausea—Dexamethasone—psoriasis	6.62e-05	0.00018	CcSEcCtD
Bicalutamide—Urticaria—Methotrexate—psoriasis	6.44e-05	0.000175	CcSEcCtD
Bicalutamide—Dizziness—Prednisone—psoriasis	6.42e-05	0.000175	CcSEcCtD
Bicalutamide—Body temperature increased—Methotrexate—psoriasis	6.41e-05	0.000175	CcSEcCtD
Bicalutamide—Abdominal pain—Methotrexate—psoriasis	6.41e-05	0.000175	CcSEcCtD
Bicalutamide—AR—SIDS Susceptibility Pathways—TNF—psoriasis	6.21e-05	0.00195	CbGpPWpGaD
Bicalutamide—Vomiting—Prednisone—psoriasis	6.17e-05	0.000168	CcSEcCtD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	6.16e-05	0.00193	CbGpPWpGaD
Bicalutamide—Rash—Prednisone—psoriasis	6.12e-05	0.000167	CcSEcCtD
Bicalutamide—Dermatitis—Prednisone—psoriasis	6.11e-05	0.000166	CcSEcCtD
Bicalutamide—Headache—Prednisone—psoriasis	6.08e-05	0.000165	CcSEcCtD
Bicalutamide—Hypersensitivity—Methotrexate—psoriasis	5.97e-05	0.000163	CcSEcCtD
Bicalutamide—Asthenia—Methotrexate—psoriasis	5.82e-05	0.000158	CcSEcCtD
Bicalutamide—Nausea—Prednisone—psoriasis	5.76e-05	0.000157	CcSEcCtD
Bicalutamide—Pruritus—Methotrexate—psoriasis	5.74e-05	0.000156	CcSEcCtD
Bicalutamide—AR—Gene Expression—CARM1—psoriasis	5.72e-05	0.00179	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—TP53—psoriasis	5.62e-05	0.00176	CbGpPWpGaD
Bicalutamide—Diarrhoea—Methotrexate—psoriasis	5.55e-05	0.000151	CcSEcCtD
Bicalutamide—Dizziness—Methotrexate—psoriasis	5.36e-05	0.000146	CcSEcCtD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	5.28e-05	0.00166	CbGpPWpGaD
Bicalutamide—Vomiting—Methotrexate—psoriasis	5.16e-05	0.00014	CcSEcCtD
Bicalutamide—Rash—Methotrexate—psoriasis	5.11e-05	0.000139	CcSEcCtD
Bicalutamide—Dermatitis—Methotrexate—psoriasis	5.11e-05	0.000139	CcSEcCtD
Bicalutamide—Headache—Methotrexate—psoriasis	5.08e-05	0.000138	CcSEcCtD
Bicalutamide—AR—SIDS Susceptibility Pathways—IL6—psoriasis	5.01e-05	0.00157	CbGpPWpGaD
Bicalutamide—AR—Generic Transcription Pathway—PPARG—psoriasis	4.94e-05	0.00155	CbGpPWpGaD
Bicalutamide—Nausea—Methotrexate—psoriasis	4.82e-05	0.000131	CcSEcCtD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	4.66e-05	0.00146	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—NDUFA5—psoriasis	4.47e-05	0.0014	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	4.17e-05	0.00131	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—NDUFA5—psoriasis	4.11e-05	0.00129	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—NDUFA5—psoriasis	4.08e-05	0.00128	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—CYP2S1—psoriasis	3.8e-05	0.00119	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.8e-05	0.00119	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—CYP2S1—psoriasis	3.5e-05	0.0011	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—CYP2S1—psoriasis	3.46e-05	0.00109	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—VDR—psoriasis	3.41e-05	0.00107	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—NDUFA5—psoriasis	2.69e-05	0.000843	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—PPARG—psoriasis	2.38e-05	0.000746	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—CYP2S1—psoriasis	2.29e-05	0.000717	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.99e-05	0.000624	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—CARM1—psoriasis	1.86e-05	0.000582	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.82e-05	0.000569	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.73e-05	0.000544	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—CARM1—psoriasis	1.71e-05	0.000535	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—CARM1—psoriasis	1.69e-05	0.000531	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.58e-05	0.000496	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—CAT—psoriasis	1.14e-05	0.000358	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—CARM1—psoriasis	1.12e-05	0.00035	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—CAT—psoriasis	1.05e-05	0.000329	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—CAT—psoriasis	1.04e-05	0.000326	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—APOE—psoriasis	8.87e-06	0.000278	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—APOE—psoriasis	8.16e-06	0.000256	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—APOE—psoriasis	8.09e-06	0.000254	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—PPARG—psoriasis	7.73e-06	0.000242	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—PPARG—psoriasis	7.11e-06	0.000223	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—PPARG—psoriasis	7.04e-06	0.000221	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—CAT—psoriasis	6.86e-06	0.000215	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—APOE—psoriasis	5.33e-06	0.000167	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—PPARG—psoriasis	4.65e-06	0.000146	CbGpPWpGaD
